AU · rank #15 · 2026-10-23
SRT3
XETRA · EUR · $20.71B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.105 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $273.63 | +0.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +19.95% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.21 |
| Gross margin TTM | +45.7% |
| 52w high | $282.20 |
| Market cap (USD) | $20.71B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Sartorius is a global life sciences partner providing single-use bioprocessing equipment, bioreactors, filtration systems, and laboratory instruments to biopharmaceutical manufacturers.
Rationale
The analyst upside signal is supported by recent Q3 revenue and EBITDA beats above consensus, positive 30-day EPS revisions with 70% analyst agreement, and an upgraded full-year outlook for Lab Products & Services.
Material risks
- 1Platform competition and supply chain localization from Danaher (Cytiva), Thermo Fisher, and Merck KGaA could erode single-use bioprocessing share and qualification-related customer switching costs.
- 2Elevated leverage at 3.33x net debt/EBITDA increases sensitivity to potential biopharma capex slowdowns or U.S. tariff-related revenue offsets up to €40 million.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.